Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Methodologic issues in epidemiologic risk assessment.

M Nurminen1, T Nurminen, C F Corvalán

  • 1Department of Epidemiology and Biostatistics, Finnish Institute of Occupational Health, Helsinki.

Epidemiology (Cambridge, Mass.)
|September 1, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial.

Clinical rheumatology·2018
Same author

Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial.

Clinical rheumatology·2018
Same author

Early Disease Activity or Clinical Response as Predictors of Long-Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis.

Arthritis care & research·2016
Same author

Long-Term Maintenance of Improvements in Patient-Reported Outcomes With Certolizumab Pegol in Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 96-Week Results of the Rapid-Axspa Study.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same author

Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis.

Arthritis care & research·2016
Same author

Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial.

Arthritis & rheumatology (Hoboken, N.J.)·2014
Same journal

Can the All of Us sample be reweighted to mirror a nationally representative sample? A comparison of mortality predictors.

Epidemiology (Cambridge, Mass.)·2026
Same journal

Gut health, systemic inflammation, and linear growth among Indonesian infants: findings from the Action Against Stunting Hub observation cohort: Erratum.

Epidemiology (Cambridge, Mass.)·2026
Same journal

Evaluating Estimators in Partially Identified Models.

Epidemiology (Cambridge, Mass.)·2026
Same journal

Stratification and accumulation? Explaining changing mortality inequities between business owners and non-owners in the U.S. (1984-2022).

Epidemiology (Cambridge, Mass.)·2026
Same journal

Be wary of age-stratum aging in early-onset cancer trends.

Epidemiology (Cambridge, Mass.)·2026
Same journal

The Authors Respond.

Epidemiology (Cambridge, Mass.)·2026
See all related articles

This review highlights challenges in epidemiological risk assessment for occupational and environmental exposures. Presenting precise, disaggregated risk data with varied models is crucial for informed health policy.

Area of Science:

  • Environmental Health
  • Epidemiology
  • Risk Assessment

Background:

  • Occupational and environmental exposures pose health risks.
  • Epidemiology is crucial for assessing these health risks.

Purpose of the Study:

  • To review methodologic issues in applying epidemiology to risk assessment.
  • To discuss concerns in presenting risk assessment results.

Main Methods:

  • The paper reviews the four phases of health risk assessment: hazard identification, exposure assessment, dose-response assessment, and risk characterization.
  • Methodologic limitations, assumptions, and subjective choices in risk assessment are discussed.
  • The assessment of health impacts from silica exposure serves as an illustration.

Related Experiment Videos

Main Results:

  • Risk assessment involves inherent uncertainties due to data limitations and subjective choices.
  • Presenting risk estimates requires careful consideration of precision and population heterogeneity.
  • The application of different scenarios and risk models is recommended.

Conclusions:

  • Accurate risk assessment necessitates transparent reporting of uncertainties and precision.
  • Disaggregated data presentation is vital to avoid losing information on population differences.
  • Employing diverse risk models enhances the robustness of health policy recommendations.